Published: August 2023
Roots Analysis has announced the addition of “Deep Learning in Drug Discovery and Deep Learning in Diagnostics Market (2nd Edition), 2023-2035” report to its list of offerings.
The traditional statistical tools and techniques available for medical data interpretation are known to be associated with challenges related to time and cost. This has prompted industry stakeholders to explore the applications of deep learning-based technologies, specifically across drug discovery and diagnosis. In addition, recent investments made in this domain are likely to offer lucrative opportunities to companies offering deep learning based technologies / solutions within the healthcare industry.
To order this 320+ page report, which features 158+ figures and 146+ tables, please visit this link
The current market landscape is dominated by the presence of small players, which constitute 57% of the total number of stakeholders. It is worth mentioning that, amongst these, over 47% of the players are based in North America.
Of these, more than 40% of the players are based in Europe. This is followed by players headquartered in North America, accounting for around 34% of the start-ups focused on deep learning in drug discovery. Further, over 55% of the start-ups engaged in this domain primarily focus on medical diagnosis.
It is important to mention that, between 2019 and 2022, majority of the amount was raised through venture capital rounds (62%) and secondary offerings (16%). Further, more than 55% of the funding instances were reported by players based in North America. Overall, more than 215 investors have actively financed various projects / initiatives focused on deep learning.
Based on inputs gathered from both secondary and primary sources, the report features an informed and insightful section estimating the cost-saving potential associated with deep learning-based solutions in drug discovery and diagnostics. In fact, the adoption of such technologies has the potential to save more than USD 22.3 billion in diagnostics by 2035.
In addition, the market in Europe is likely to grow at a relatively faster pace (CAGR of 23.7%) in the long term. Further, in 2035, deep learning in the drug discovery market for oncological disorders is expected to capture the majority share (36%) of the total market.
In terms of therapeutic area, majority of the revenues (34%) are likely to come in from deep learning technologies being used for the diagnosis of oncological disorders. On the other hand, the deep learning market for diagnosis of musculoskeletal disorders is expected to grow at a faster pace (CAGR of 22.9%) during the forecasted period.
To request a sample copy / brochure of this report, please visit this link
The financial opportunity associated with the deep learning in drug discovery and deep learning in diagnostics market has been analyzed across the following segments:
The opinions and insights presented in the report were also influenced by discussions held with eminent stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
The research also includes profiles of key players (listed below) employing deep learning solutions for drug discovery and diagnostics purposes; each profile features a brief overview of the company, its financial information, service portfolio, recent developments and an informed future outlook.
For additional details, please visit https://www.rootsanalysis.com/reports/view_document/deep-learning-in-drug-discovery-market/156.html
or email firstname.lastname@example.org
You may also be interested in the following titles:
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES